Open AccessPI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Author(s) -
Sigrid S. Skånland,
Jennifer R. Brown
Publication year - 2022
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2022.281266
Subject(s) - idelalisib , medicine , chronic lymphocytic leukemia , tolerability , dosing , regimen , pi3k/akt/mtor pathway , clinical trial , pharmacology , intensive care medicine , oncology , leukemia , adverse effect , ibrutinib , biology , apoptosis , biochemistry